Ivana Magautsevich-Libish, President and CEO of Vigil Neuroscience, Inc. (NASDAQ: VIGL ), a clinical-stage biotech company with a market capitalization of $92 million, recently acquired 5,000 shares of the company’s common stock. According to InvestingPro analysis, the stock is currently trading below its fair value, indicating a potential upside opportunity. The shares were purchased on December 5 at a weighted average price of $2.34 per share, for a total transaction amounting to $11,700. This purchase increases Magovcevic-Liebisch’s direct ownership to 212,687 shares. Shares were bought in multiple trades between $2.33 and $2.34. InvestingPro The data shows that the stock is currently in oversold territory, with the price down more than 33% over the past six months. The company maintains a strong liquidity position with a current ratio of 3.72, although investors should note that more than 10 additional disclosures are available with a subscription to InvestingPro.
In other recent news, Vigil Neuroscience earned an Outperform rating from William Blair, with the firm setting a fair price of $18.67 per share. The company is advancing the treatment of Alzheimer’s disease by focusing on the development of therapeutics targeting TREM2. This approach could potentially address the needs of a broad population of patients suffering from CNS-related degenerative diseases.
Vigil Neuroscience also reported promising results from its Phase I study of VG-3927, a treatment for Alzheimer’s disease. Following these developments, Guggenheim reaffirmed its Buy rating on the company, while JMP Securities maintained its Market Performer rating and $23.00 target price on the stock.
The US Food and Drug Administration (FDA) has lifted a partial clinical suspension of Vigil Neuroscience’s Phase 1 clinical trial of VG-3927, allowing the company to potentially increase the drug’s exposure limit in the ongoing study. The company plans to report full Phase 1 data, including results from a cohort of Alzheimer’s patients, in the first quarter of 2025.
Guggenheim, on the other hand, reiterated its “Buy” rating on Vigil Neuroscience after Alector (NASDAQ: ) announced results from a Phase II trial for Alzheimer’s disease. The company remains bullish on its own Alzheimer’s treatment VG-3927, a small-molecule TREM2 agonist.
Finally, JMP Securities maintained a Market Perform rating and a $23.00 price target on Vigil Neuroscience shares, pending Phase 2 results for Alector’s AL002, which may provide validation for Vigil Neuroscience’s small molecule TREM2 agonist, VG-3927.
This article was powered by AI and reviewed by an editor. For more information, see our Terms and Conditions.
